ILMN Illumina, Inc.

200.65USD-4.45%Mkt Cap: 30.34B USDP/E: 34.54

Illumina, Inc. provides sequencing- and array-based solutions for genetic and genomic analysis in the Americas, Europe, Greater China, the Asia Pacific, the Middle East, and Africa. The company offers sequencing- and arr…

Insiders, last 90 daysNet sellers
Institutional holders20 on file

Key Statistics

Company
Market Cap30.34B USD
Enterprise Value32.73B USD
Revenue (TTM)4.54B USD
Gross Profit2.87B USD
Net Income (TTM)850.00M USD
Revenue/Share29.86 USD
Last Price200.65 USD
Fiscal Year EndDec 2025
MR QuarterSep 2026
Employees8.6K
CountryUS
SectorHealthcare
IndustryDiagnostics & Research
ISIN—
Valuation
P/E (Trailing)34.54
P/E (Forward)32.45
PEG2.58
EV/EBITDA28.66
EV/Revenue7.21
P/S6.68
P/B9.70
EPS (TTM)5.74 USD
EPS (Forward)6.18 USD
52W Range
112.6545% of range309.35
52W High309.35 USD
52W Low112.65 USD
Profitability
Gross Margin66.08%
Oper. Margin19.06%
EBITDA Margin25.16%
Profit Margin19.57%
ROE31.22%
ROA12.79%
ROIC17.55%
ROCE16.15%
Growth
Revenue Growth4.20%
Earnings Growth45.90%
Cash Flow & Leverage
Operating CF1.08B USD
CapEx (TTM)148.00M USD
FCF Margin18.92%
FCF Yield2.83%
Net Debt976.00M USD
Net Debt/EBITDA0.85
Net Debt/FCF1.14
Balance Sheet
Debt/Equity0.94
Current Ratio2.63
Quick Ratio1.87
Book Value/Sh20.69 USD
Cash/Share8.84 USD
Dividends
Fwd Div Rate—
Trail. Div Rate0.00 USD
Div. Yield0.00%
5Y Avg Yield—
Payout Ratio0.00%
Ex-Div Date—
Pay Date—
Splits
Last Split1028:1000
Split DateJun 25, 2024
Analyst Consensus
Rating2.5 (Buy)
Strong BuyBuyHoldSellStr. Sell
Target (Mean)261.45 USD
Upside (mean)+30.3%
Target Range165.00 USD – 365.00 USD
165.00+30.3% to mean365.00
# Analysts20
Ownership
Shares Out.151.20M
Float150.69M
Insiders0.23%
Institutions109.20%
Short Interest
Short Ratio3.2d
Short % Float8.67%
Short % Out.5.31%
Shares Short8.02M
Short (prev mo.)9.47M
Technical
SMA 50248.62 (-19.3%)
SMA 200179.78 (+11.6%)
Beta1.45
S&P 52W Chg12.08%
Avg Vol (30d)2.13M
Avg Vol (10d)2.11M
Technical Indicators
RSI (14)36.2
MACD-14.8648
MACD Signal-12.1811
MACD Hist.-2.6837
BB Upper293.09 USD
BB Middle231.18 USD
BB Lower169.28 USD
BB Width53.55%
ATR (14)14.08 USD
Vol Ratio (20d)0.75x

About Illumina (NASDAQ: ILMN)

›

Illumina (NASDAQ: ILMN) is listed on Nasdaq, where its shares trade in USD. It belongs to the Diagnostics & Research industry, part of the Healthcare sector, and reports about 8,600 employees.

The shares were at 200.65 USD on 19 November 2026, up 65.7% over 52 weeks. Its 52-week range is 112.65 USD to 309.35 USD: the price is 35.1% below the high and 78.1% above the low.

At a market capitalisation of 30.34B USD, it trades at 34.5 times trailing earnings and 32.5 times forward earnings. The median trailing P/E of its 18 largest Diagnostics & Research peers is 35.8, so ILMN is valued in line with them.

Illumina reports return on equity of 31.2%, an operating margin of 19.1% and revenue up 4.2% year over year.

Its debt exceeds its cash by 976.00M USD, a debt-to-equity ratio of 0.94. Its Piotroski F-score is 8 out of 9, a strong reading of its financial health. 20 analysts cover the stock, with an average rating of Buy; their mean price target of 261.45 USD is 30.3% above the current price. The next earnings report is expected on 4 February 2027.